Gilead – $5B Tubulis Acquisition

Summary Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies in next-generation oncology pipelines. What Happened Gilead entered into an…